Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMC I109V

Next Previous
Search
Drug Profile

IMC I109V

Alternative Names: Envelope-A02; IMC-I109V; ImmTAV-Env

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunocore
  • Class Anti-infectives; Antivirals; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatitis B

Most Recent Events

  • 15 Oct 2024 Immunocore withdraws enrollment from the phase II portion of the phase I/II trial in Hepatitis B in Australia, Denmark, Hong Kong, South Korea, Romania, Spain, Taiwan, United Kingdom, United States, Belgium, New Zealand, Poland (IV) (NCT05867056) (EudraCT-2019-004212-64)
  • 25 Jun 2022 Pharmacokinetics, efficacy and safety data from a phase I/II trial in Hepatitis B released by Immunocore
  • 22 Jun 2022 Initial efficacy, adverse events and pharmacokinetics data from a phase I trial in Hepatitis B presented at the International Liver Congress 2022 (ILC-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top